Prelude Therapeutics (PRLD) Cash from Financing Activities (2019 - 2026)

Prelude Therapeutics has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$314000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$314000.0, down 96.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.7 million (up 9371.43% YoY), and the FY2025 annual result was $24.8 million, up 20780.0% from the prior year.
• Cash from Financing Activities came in at -$314000.0 for Q1 2026 at Prelude Therapeutics, down from $24.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $111.3 million in Q2 2023 to a low of -$41.0 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is $37000.0 (2025), against an average of $9.5 million.
• Across the five-year window, Cash from Financing Activities sank 9824.17% in 2022 and surged 73464.71% in 2025, its largest moves.
• Prelude Therapeutics' Cash from Financing Activities stood at $155000.0 in 2022, then surged by 16181.94% to $25.2 million in 2023, then sank by 100.13% to -$34000.0 in 2024, then soared by 73464.71% to $24.9 million in 2025, then slumped by 101.26% to -$314000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$314000.0 (Q1 2026), $24.9 million (Q4 2025), and -$5000.0 (Q3 2025), per Business Quant data.